Related Experiment Video
Updated: Feb 8, 2026

A Mouse Model of the Cornea Pocket Assay for Angiogenesis Study
Published on: August 18, 2011
Out-of-pocket medical expenses in severe CHD
Justin J Elhoff1, Kimberly E McHugh2, Jason R Buckley2
11Texas Children's Hospital,Department of Pediatrics,Baylor College of Medicine,Houston,TX,USA.
Insights
Families with commercially insured children needing surgery for severe congenital heart defects (CHD) faced average out-of-pocket costs of nearly $3000 in the first year. This study quantifies financial burdens for these families.
Area of Science:
- Pediatric Cardiology
- Health Economics
- Medical Finance
Background:
- Families of children with congenital heart defects (CHD) experience significant financial stress due to unpredictable medical costs.
- Understanding the financial burden is crucial for supporting families and informing healthcare policy.
Purpose of the Study:
- To assess the out-of-pocket healthcare expenses incurred by families of commercially insured infants undergoing surgery for severe CHD within the first 12 months of life.
Main Methods:
- Utilized the MarketScan database (2010-2012) to identify infants with specific severe CHD diagnoses (transposition of the great arteries, tetralogy of Fallot, truncus arteriosus) requiring surgical repair.
- Extracted family financial responsibilities, including co-payments, deductibles, and co-insurance, for the initial year post-diagnosis.
Main Results:
- Identified 481 infants meeting the study criteria.
- Average family out-of-pocket costs were $2928 for the first year, with no significant difference across the studied CHD types.
- Costs ranged widely from $50 to $18,167, with initial hospitalization and outpatient care being the primary cost drivers.
Conclusions:
- Commercially insured families with infants undergoing surgery for severe CHD incur average out-of-pocket healthcare costs of approximately $3000 in the first year.
- While the average cost provides a benchmark, the considerable variation highlights the need for financial planning and support.
- Findings can inform healthcare policy discussions and help alleviate financial uncertainty for affected families.
Abstract:
IntroductionFamilies of children born with CHD face added stress owing to uncertainty about the magnitude of the financial burden for medical costs they will face. This study seeks to assess the family responsibility for healthcare bills during the first 12 months of life for commercially insured children undergoing surgery for severe CHD.
Methods:
The MarketScan ® database from Truven was used to identify commercially insured infants in 39 states from 2010 to 2012 with an ICD-9 diagnosis code for transposition of the great arteries, tetralogy of Fallot, or truncus arteriosus, as well as the corresponding procedure code for complete repair. Data extraction identified payment responsibilities of the patients' families in the form of co-payments, deductibles, and co-insurance during the 1st year of life.
Results:
There were 481 infants identified who met the criteria. Average family responsibility for healthcare bills during the 1st year of life was $2928, with no difference between the three groups. The range of out-of-pocket costs was $50-$18,167. Initial hospitalisation and outpatient care accounted for the majority of these responsibilities.
Conclusions:
Families of commercially insured children with severe CHD requiring corrective surgery face an average of ~$3000 in out-of-pocket costs for healthcare bills during the first 12 months of their child's life, although the amount varied considerably. This information provides a framework to alleviate some of the uncertainty surrounding healthcare financial responsibilities, and further examination of the origination of these expenditures may be useful in informing future healthcare policy discussion.
Related Concept Videos
Inhaled Medications
Endocarditis III: Medical Management
Myocarditis III: Medical Management
Pericarditis III: Medical Management
Heart Failure V: Medical Management
Mitral Stenosis III: Medical Management

